|
May 14
|
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
|
|
May 10
|
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call Transcript
|
|
May 9
|
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
|
|
May 2
|
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
|
|
Apr 11
|
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
|
|
Mar 25
|
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 18
|
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
|
|
Jan 16
|
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
|
|
Jan 9
|
Anavex (AVXL): Strong Industry, Solid Earnings Estimate Revisions
|
|
Jan 8
|
5 Small-Cap Stocks to Play the January Effect
|
|
Jan 8
|
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
|
|
Dec 20
|
Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA
|
|
Dec 20
|
Anavex Life Sciences Stock Sees RS Rating Jump To 86; Is It One To Watch?
|
|
Dec 20
|
Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome
|
|
Dec 19
|
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
|
|
Dec 18
|
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 401.47% as Wall Street Analysts Expect?
|
|
Dec 10
|
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
|
|
Dec 1
|
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q4 2023 Earnings Call Transcript
|
|
Nov 30
|
Wall Street Analysts See a 468.83% Upside in Anavex Life Sciences (AVXL): Can the Stock Really Move This High?
|
|
Nov 27
|
Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
|